Recent Finacing
Recent Raise
CODA Biotherapeutics is a preclinical biopharma developing AAV‑delivered chemogenetic gene therapies that express engineered inhibitory receptors in target neurons, activated by oral small‑molecule agonists for neuropathic pain and epilepsy.
